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Abstract
Background
Giardiasis is an intestinal infection correlated with poverty and poor drinking water quality,
and treatment options are limited. According to the Center for Disease Control and Preven-
tion, Giardia infections afflict nearly 33% of people in developing countries, and 2% of the
adult population in the developed world. This study describes the single cyclic nucleotide-
specific phosphodiesterase (PDE) of G. lamblia and assesses PDE inhibitors as a new gen-
eration of anti-giardial drugs.
Methods
An extensive search of the Giardia genome database identified a single gene coding for a
class I PDE, GlPDE. The predicted protein sequence was analyzed in-silico to characterize
its domain structure and catalytic domain. Enzymatic activity of GlPDE was established by
complementation of a PDE-deficient Saccharomyces cerevisiae strain, and enzyme kinetics
were characterized in soluble yeast lysates. The potency of known PDE inhibitors was
tested against the activity of recombinant GlPDE expressed in yeast and against proliferat-
ing Giardia trophozoites. Finally, the localization of epitope-tagged and ectopically
expressed GlPDE in Giardia cells was investigated.
Results
Giardia encodes a class I PDE. Catalytically important residues are fully conserved between
GlPDE and human PDEs, but sequence differences between their catalytic domains sug-
gest that designing Giardia-specific inhibitors is feasible. Recombinant GlPDE hydrolyzes
cAMP with a Km of 408 μM, and cGMP is not accepted as a substrate. A number of drugs
exhibit a high degree of correlation between their potency against the recombinant enzyme
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and their inhibition of trophozoite proliferation in culture. Epitope-tagged GlPDE localizes as
dots in a pattern reminiscent of mitosomes and to the perinuclear region in Giardia.
Conclusions
Our data strongly suggest that inhibition of G. lamblia PDE activity leads to a profound inhibi-
tion of parasite proliferation and that GlPDE is a promising target for developing novel anti-
giardial drugs.
Author summary
Cellular signaling by the cyclic nucleotides cAMP and cGMP is ubiquitously found in
organisms from human to unicellular parasites. Cyclic nucleotide-specific phosphodies-
terases (PDEs) are pivotal regulators of these signaling processes and these enzymes repre-
sent important drug targets for a variety of diseases. Eleven PDE families are
distinguished in humans and selective inhibition of a single human PDE family without
targeting others is feasible. In parasites, interference in the signaling mechanism by PDE
inhibition may be fatal. The diarrhea-causing parasite Giardia lamblia contains only one
single PDE, named GlPDE. GlPDE activity is highly impaired by a range of PDE inhibi-
tors, which also suppress parasite proliferation in vitro. Thus, there is a good agreement
between PDE inhibition and parasite drug susceptibility. We demonstrate molecular dif-
ferences between human PDEs and GlPDE that can be exploited for the development of
GlPDE-selective inhibitors. Finally, our data may suggest localization of GlPDE to mito-
some organelles, which are absent in human cells and thus are in the focus as possible tar-
gets for the treatment of giardiasis. This may add to the notion that GlPDE represents a
potential target for the development of novel anti-giardial drugs.
Introduction
Giardia lamblia is a protozoan parasite that causes giardiasis, an intestinal disease with symp-
toms such as diarrhea, nausea, and malabsorption [1]. Trophozoites are the disease-causing
stage and colonize the upper small intestine of humans and other vertebrates. They form cysts,
which are shed into the environment via the fecal route and which are then orally transmitted,
mostly via contaminated water. Giardiasis occurs worldwide, predominantly in resource-poor
countries with low standards of sanitation, and represents a major cause of non-bacterial diar-
rhea with 280 million symptomatic human cases every year [2]. In developing countries, infec-
tion rates of 10% to 30% are common, though rates of 40% and higher have been reported in
some instances [3,4]. Chronic or recurrent giardiasis in early childhood is associated with poor
cognitive function and failure to thrive [5].
Metronidazole (commercially known as Flagyl) and other nitroimidazoles are being used as
a therapy of choice since the 1960s. However, resistance against metronidazole has been
described [6,7]. Consequently, substitution therapies including the benzimidazole albendazole,
the acridine derivative quinacrine—or the aminoglycoside paromomycin, alone or in combi-
nation with metronidazole [8,9], are of increasing importance. New therapies are urgently
needed because current treatments (i) depend on repeated dosing schedules (suboptimal for
developing countries), (ii) have adverse effects, (iii) are ineffective in up to 20% of cases and
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(iv) clinical or laboratory-induced resistance has been reported for most of the current anti-
giardial drugs [10,11].
Phosphodiesterases (PDEs) are key enzymes of cyclic nucleotide signaling. They constitute
the only enzymes for hydrolyzing the signaling molecules cAMP and cGMP and thus are cru-
cially important regulators of the temporal and spatial shape of the cyclic nucleotide signals.
Three structurally distinct classes of PDEs have been described [12]. Thereof only class I
enzymes have been identified in protozoan parasites and their mammalian hosts so far. Human
PDEs (hPDEs) comprise eleven class I families (hPDE1–11), which differ with respect to sub-
strate-specificity, regulation and distribution in tissues as well as in intracellular compartments.
The catalytic domains of class I PDEs are highly conserved at the level of their three-dimen-
sional structures, though the different families share only 20–50% amino acid sequence identity
within their catalytic domains (S1 Table). Small differences in structure and sequence of their
catalytic pockets account for substrate selectivity (cAMP versus cGMP) and—most importantly
—have allowed the development of family-specific PDE inhibitors [13]. Most hPDE families are
being actively studied as potential drug targets against a wide range of medical conditions and a
number of PDE inhibitors are currently marketed for various conditions such as chronic
obstructive pulmonary disease, psoriatic arthritis or erectile dysfunction [14,15].
The extensive available knowledge on PDE structure, physiology and pharmacology has
prompted the study of PDEs as potential targets for the treatment of infectious diseases. In Try-
panosoma brucei, the causative agent of African sleeping sickness, targeting PDEs by genetic or
pharmacological means led to rapid parasite death in vitro and to the elimination of infections
in vivo [16]. Two inhibitors developed against the trypanosomal PDEs TbrPDEB1 and
TbrPDEB2, namely NPD-001 and VUF13525, exhibit potencies in the nanomolar range
[17,18]. Recent studies in the malaria parasite Plasmodium falciparum have demonstrated that
a PDE-inhibitor with specificity to a PDE expressed in the merozoite stage of the parasite led
to the premature egress of merozoites, thus interrupting the multiple cycles of reinvasion and
multiplication [19]. In addition, genetic deletion of PDEγ in the rodent malaria pathogen Plas-
modium yoelii blocked sporozoite motility and parasite transmission [20]. In Giardia, cAMP
has been suggested to be involved in excystation [21] and encystation [22], and a potential role
in regulating trophozoite attachment and locomotion was hypothesized based on the intracel-
lular localization of the protein kinase A (gPKA) [21]. Thus, PDEs could play a vital role in the
biology of this parasite.
In this study, we show that the repertoire of PDEs in the genome of the intestinal parasite
G. lamblia is restricted to a single gene coding for a class I PDE (GlPDE). We expressed
GlPDE lacking its N-terminal transmembrane helix region in yeast and characterized its enzy-
matic activity. We also show that the inhibition profile of a set of well-characterized inhibitors
for human PDEs shows a good correlation between enzymatic GlPDE inhibition and anti-par-
asitic activity, and we have indication that GlPDE is associated with mitosomes, which are
relic organelles in G. lamblia. Our results suggest that GlPDE represents a novel, and poten-
tially promising drug target that should be further exploited for the development of novel and
urgently needed medication against giardiasis.
Materials and methods
Materials
Resazurin sodium salt (cat. R7017), dimethyl sulfoxide (DMSO, cat. D8418) as well as cAMP
and cGMP (sodium salts) were obtained from Sigma (Buchs, Switzerland). Radiochemicals
were from Hartmann Analytic (Braunschweig, Germany). PDE inhibitors were from the fol-
lowing sources: isobutyl-methyl-xanthine (IBMX), 8-methoxymethyl-IBMX, vinpocetine,
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rolipram, dipyridamole, papaverine, BAY 73–6691, BRL 50481 were from Sigma; zardaverine,
cilostamide were from BioMol Anawa Trading (Wangen, Switzerland); pentoxifylline was
from Calbiochem (Merck Millipore, Schaffhausen, Switzerland); etatolate was from Tocris
Bioscience (Lucerna-Chem, Lucerne, Switzerland); erythro-9-(2-hydroxy-3-nonyl)adenine
(EHNA), milrinone, trequinsin, Ro 20–1724, dipyridamole, zaprinast were obtained from
Fisher Scientific; BAY 60–7550 was from Biotrend Chemicals (Destin, FL, USA), sildenafil cit-
rate was generously provided by Pfizer, Inc. The following compounds were synthesized using
methods previously described: NEU28 (syn. PQ-10, CAS 927691-21-2) [23], NEU222 [24],
PFE-PDE1 (patent EP911333A1) [24], PFE-PDE9 (patent WO2003037899A1) [24], tadalafil
[25], piclamilast (patent WO9212961), roflumilast (patent WO9501338), NPD-001 (syn.
CpdA, PPS54019) [26,17] and VUF13525 (compound 20b in Orrling KM et al (2012) [18]).
In silico sequence analyses
The HMMER software package (version 3.1b1) was used to search the GiardiaDB databases (v
4.0) of annotated proteins and translated open reading frames (ORFs) for the presence of
PDEs belonging to either of the currently established three PDE classes I, II and III [27]. The
profile hidden Markov models (HMMs) were generated from multiple sequence alignments of
each PDE class: The HMM of class I PDEs was built from 24 catalytic domain sequences com-
prising one member of all 11 human PDE families, PDEs from kinetoplastid and plasmodial
parasites, as well as PDEs from Drosophila melanogaster, Caenorhabditis elegans and Saccharo-
myces cerevisiae. The HMM of class II PDEs is based on all 7 manually annotated sequences in
the Swiss-Prot database (release2014-04; entries CPDP_ALIFS, CPDP_YERPE, PDE1_CA-
NAX, PDE1_DICDI, PDE1_SCHPO, PDE1_YEAST, PDE7_DICDI). To identify potential
class III PDEs, two HMMs were created: (a) by using the twenty most diverse members of the
NCBI CDD family PRK11148 (http://www.ncbi.nlm.nih.gov/cdd); (b) by using a seed align-
ment of 49 sequences contained in the HAMAP profile MF_00905 [28]. All hits above the sig-
nificance threshold (e < 0.0001) were analyzed manually.
Sequence patterns searches were done with the programs fuzzpro and patmatdb (EMBOSS
software package, http://emboss.open-bio.org). Used consensus search patterns were: H-D-
[LIVMFY]-x-H-x-[AG]-x(2)-[NQ]-x-[LIVMFY] (class I PDEs, Prosite PS00126), H-x-
H-L-D-H-[LIVM]-x-[GS]-[LIVMA]-[LIVM](2)-x-S-[AP] (class II PDEs, Prosite PS00607),
D-x(1,1000)-G-D-x(1,1000)-G-N-H-[ED]-x(1,1000)-H-x(1,1000)-G-H-x-H (extended dime-
tallophosphoesterase pattern).
Multiple sequence alignments (MSAs) were created using MSAprobs [29] (profile-based algo-
rithm) and Expresso [30] (structure-guided algorithm) and then manually refined by incorporat-
ing information of solved PDE structures. Conservation scoring analysis of MSAs was done
using valdar01 and trident scoring algorithms [31]. Identity scores were calculated using a self-
written Python script. Transmembrane helices were predicted using the programs TOPCONS
2.0 [32] (metasearch with five programs), PSIPRED [33] (MEMSAT-SVM and MEMSAT3 algo-
rithms), Phobius/PolyPhobius [34], TMHMM 2.0 [35], TMSEG, PHDhtm [36], TMPred [37]
and TopPred [38], and a consensus was deduced from all predictions. Secondary structure pre-
dictions were done using iTasser, PSSpred and the “Predict Protein” web services [39,36].
Giardia lamblia cell culture
G. lamblia WBC6 (ATCC catalogue number 50803) trophozoites were grown under microaer-
ophilic conditions in 11 ml culture tubes (Nunc, cat. 156758) containing TYI-S- 33 medium
supplemented with 10% bovine serum and bovine bile according to standard protocols [40].
Parasites were harvested by chilling the tubes on ice for 30 minutes to detach adherent cells
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and collected by centrifugation (900 x g, 10 minutes, 4˚C). Encystation was induced using the
two-step method as described previously [41] by cultivating the trophozoites in bile-free
medium for 44 hours and thereafter in medium (pH 7.85) containing porcine bile.
Expression in yeast
The DNA sequence comprising the catalytic domain (residues Gly-983 –Glu-1371) was ampli-
fied by PCR using genomic DNA of G. lamblia WBC6 and the primer pair GlPDE1cat-for (5’-
GCAGTCGACATATGGGAGTGGATTGTTCAAATATCAAGTTGG-3’) and GlPDE1cat-rev
(5’-CGTGGATCCTATTACTCCTTCTTGTCCAGCTCAATCTC-3’). The PCR product was
then cloned into the TA vector pCRII-TOPO (Invitrogen) yielding plasmid pCR-GlPDE1cat.
To get a plasmid containing the sequence coding for the full length protein lacking the N-ter-
minal transmembrane helices (Met-588 –Glu-1371) of GlPDE, a further PCR product was pro-
duced using the primer pair GlPDE1-Mfor (5’-GAGCAGTCGACATATGCCGTGTGTTTT
GTTTCGACTGG-3’) and GlPDE1-LMrev (5’-GGTCTGCATGAGAACAGTACACGGTAC
TGAGCATG-3’) and was cloned via NdeI (bold) and BsrGI into pCR-GlPDE1cat resulting in
plasmid pCR-GlPDE1M. The inserts of both plasmid constructs were verified by sequencing
and subcloned into two variants of the yeast expression vector pLT1 [42] using the restriction
enzymes SalI (italic)/EcoRV or NdeI (bold)/EcoRV. The EcoRV cloning site originated from
the multiple cloning site of the pCRII-TOPO vector. One pLT1 variant directs the expression
of the Giardia protein alone, whereas the other adds an N-terminal hemagglutinin (HA) tag to
allow detection of the recombinant protein. Transformation of the constructs into the PDE-
deficient S. cerevisiae strain PP5 (MATa leu2-3 leu2- 112 ura3-52 his3-532 his4 cam pde1::
URA3 pde2::HIS3) was carried out as described previously [43].
Yeast complementation assay
The heat-shock assay to detect complementation of the PDE-deficient phenotype of the S. cere-
visiae strain PP5 was carried out exactly as described [43]. Yeast strains were streaked onto SC-
leu plates (selective medium lacking leucine) and grown for 2 days at 30˚C. The colonies were
then replica-plated onto YPD plates prewarmed to 55˚C, and were incubated for another 15
min at 55˚C. Plates were then cooled to room temperature and incubation was continued at
30˚C for 18–36 h.
Yeast cell extracts
Yeast cell pellets were created exactly as described previously [44]. Briefly, yeast was grown at
30˚C in SC-leu medium to end log phase and thereafter again for 3.5 h in YPD to maximize
protein expression. Washed cells were frozen in liquid nitrogen and stored at -70˚C. Frozen
cell pellets were thawed on ice and resuspended in an equal volume of ice-cold extraction
buffer (50 mM HEPES, pH 7.5, 100 mM NaCl, 1x Complete protease inhibitor cocktail without
EDTA (Roche Applied Science)). Cell lysates were produced by three passages through a high
pressure homogenizer (French press at 20’000 psi, 4˚C). Unbroken cells and cell debris were
removed by centrifugation for 20 min at 16’000 RCF at 4˚C. 25% glycerol was added to the
cleared supernatant. Aliquots were snap-frozen in liquid nitrogen and stored at -70˚C for sub-
sequent PDE activity assays.
PDE assay
PDE activity was determined by a modification of the two-step procedure of Thompson and
Appleman [45] as described previously [42]. In all reactions no more than 20% of the substrate
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was hydrolyzed. Assays were always carried out in triplicates and at 1 μM cAMP concentra-
tion. Inhibitors were dissolved and diluted in dimethyl sulfoxide (DMSO), with 1% final
DMSO concentration in the reaction mixes. Control reactions with DMSO alone were always
included. Data were analyzed using the GraphPad Prism software package (GraphPad, San
Diego).
G. lamblia trophozoite proliferation assay
Test compounds were dissolved in DMSO and serially diluted in Giardia culture medium. G.
lamblia WBC6 trophozoites were grown until adherent cells reached a confluency close to
100%. Cells were then chilled on ice for 20 min and adherent parasites were detached from the
culture tube. Cultures were diluted to 5x103 cells/ml in growth medium (room temperature)
and 100 μl aliquots were immediately added to wells of 96-well plates preloaded with the same
volume of test compound dilutions. DMSO (solvent) controls were always included. Plates
were incubated for 72 h at 37˚C in a humid chamber with an anaerobic atmosphere. Adherent
cells were then washed twice with 200 μl PBS before adding 200 μl of PBS containing 10 mg/ml
resazurin and 1% glucose. After incubation for 4 h at 37˚C, plates were read on a fluorescence
plate reader (Wallac 1420 VICTOR2, PerkinElmer) with excitation and emission wavelengths
of 544 nm and 590 nm, respectively. Data were analyzed with the GraphPad Prism software
package using a sigmoidal dose-response model for regression. All assays were done in qua-
druplicate and at least three independent experiments were performed.
Transient expression of HA-tagged GlPDE in Giardia trophozoites
C-terminally HA-tagged GlPDE was expressed under its endogenous promotor in G. lamblia
trophozoites as follows: The entire open reading frame of GlPDE (gene ID GL50803_14058)
and 43bp of the 5’-upstream region were PCR amplified from genomic DNA using the primer
pair 5’-CGTCTAGATTTGTGTCATAAGCAAGGTAA-3’ and 5’-CGTTAATTAACTA CGC
GTAGTCTGGGACATCGTATGGGTACTCCTTCTTGTCCAGCTCAA-3’. These primers
introduce a C-terminal HA-tag (underlined) and the two restrictions sites XbaI (bold) and
PacI (bold italic) into the amplicon. The XbaI/PacI-digested PCR product was cloned into vec-
tor PAC-CHA [46] and Giardia WBC6 trophozoites were transfected by electroporation using
15 μg of plasmid DNA as input (device and settings: Bio-Rad Gene Pulser, 350V, 960 μF, 800
O). Stable transfectants were selected with the antibiotic puromycin (Sigma, cat. 7699111) at a
concentration of 77 μM. Expression of the PDE is driven by its endogenous promoter in the
upstream region. The transiently transfected cells, expressing HA-tagged GlPDE under its
endogenous promoter, were used in all localization studies.
Peripheral vesicle (PV) labeling and immunofluorescence analysis
Endocytic uptake of the fluorescent dye “dextran Alexa Fluor 594” (Life Technologies, cat.
D22913) by PV organelles was achieved as described previously [47]. Briefly, trophozoites
were grown and harvested as described above. Cells were washed twice in 1x PBS (900 x g, 10
min, 4˚C) and resuspended in PBS supplemented with 5 mM cysteine, 5 mM glucose, and 0.1
mM ascorbic acid containing 4 mg/ml dextran Alexa Fluor 594. Trophozoites were transferred
to 37˚C for 30 minutes, protected from light. Samples were then washed twice in PBS (900 x g,
10 min, 4˚C), fixed in 3% formaldehyde and processed for immunofluorescence [48]. For
immunofluorescence staining, a fluorescein isothiocyanate (FITC)-conjugated mouse anti-HA
antibody (dilution 1:100; Roche Diagnostics GmbH, Manheim, Germany) was used. Prior to
inspection, specimens were embedded in Vectashield (Vector Labs, Inc, cat. H-1200) contain-
ing the DNA intercalating agent 49-6-Diamidino-2-phenylindole (DAPI).
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Immunofluorescence analysis was performed on a Nikon Eclipse 80i microscope using the
software Openlab 5.5.2 (PerkinElmer) for picture acquisition.
RNA preparation and reverse transcription
RNA was isolated from wild type cells using an RNAeasy kit (QIAGEN Cat. 74104) following
the ‘Animal Cells Spin’ protocol. A DNase I digestion was included to remove residual geno-
mic DNA according to the manufacturer’s protocol. RNA was eluted in 50 μl of RNase-free
water. Reverse transcription was performed using a Qiagen Omniscript RT kit (Cat. 205111)
and cDNA was amplified by PCR using different combination of primers.
Results
The G. lamblia genome encodes only a single class I PDE
The vast majority of genes in the Giardia Genome Database (www.GiardiaDB.org version 4.0)
[49] were annotated based on automated annotation algorithms. However, Giardia is a highly
diverged organism [50]. To enhance the detection power for a putative PDE, we performed a
comprehensive search in GiardiaDB using the HMMER software package (v 3.1b). To identify
class I PDEs, a profile hidden Markov model (HMM) was built from the catalytic domain of
24 PDE sequences, including members of all eleven hPDE families as well as a selection from
phylogenetically diverse species. This search identified a single class I PDE (GlPDE; e-
value = 4e-90) in all G. lamblia isolates sequenced so far (gene IDs GL50803_14058,
DHA2_150867, GL50581_303, GSB_153349, GLP15_4333). A putative PDE with similarity to
GlPDE was also identified in the database of annotated proteins of the salmon parasite Spiro-
nucleus salmonicida, a diplomonad species such as G. lamblia. GlPDE and the Spironucleus
PDE (SsPDE, GiardiaDB gene ID SS50377_13952) share a similar domain structure, a short
stretch of weak homology in the N-terminal protein half (185 aa with 24% identity) and 35%
identity in the C-terminal catalytic domain, indicating that both enzymes are distantly related
members of the same PDE family (see S2 Fig). To identify class II or class III PDEs [12] in G.
lamblia, the database was queried with the appropriate profile HMMs (see Materials and meth-
ods), but no corresponding protein sequences could be detected. To validate the automated
annotation of the GlPDE open reading frame, RNA from trophozoites in exponential growth
phase was reverse transcribed, and the presence of the full length GlPDE transcript was con-
firmed. No substantial alterations in the RNA expression levels during in vitro–induced tro-
phozoite-to-cyst differentiation were found in a recently published RNA-seq study [51]. In
contrast, the putative nucleotidyl cyclases identified in the GiardiaDB by means of profile
HMM searches (S1A Fig), as well as the protein kinase A subunits (gPKAr and gPKAc) display
a differential expression pattern during in vitro encystation (S1B Fig).
Domain organization of GlPDE. The open reading frame of GlPDE (GL50803_14058)
encodes a protein of 1371 amino acids (molecular mass = 154.9 kDa, pI = 7.4; see Fig 1A). The
N-terminal region (aa 1–573) is predicted to contain eight or nine transmembrane helices
(TMH). Interestingly, the first 71 residues, comprising two TMHs, are reminiscent for a pre-
dicted mitochondrial targeting signal (MitoProt II [52], p = 0.96). No significant similarity to
any sequence in the TrEMBL database could be found within the 420 amino acids between the
last TMH and the catalytic domain (aa 574–996). The highly conserved catalytic domain is
located at the C-terminus (aa 997–1371; see Fig 1A). In accordance with average homology
between Giardia genome assemblages A, B and E [50], GlPDE homologs show an overall
sequence identity of 77 to 90% (S1 File). Lowest sequence conservation is found in the 140 aa
-long region between TMH 5 and 6 (35 to 73% identity) and the highest one in the catalytic
domain (86 to 94%). All residues of the substrate-binding pocket in the catalytic domain are
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Fig 1. Domain structure of GlPDE and alignment of its catalytic domain sequence with other PDEs. (A) Schematic representation of the
domain structure. The predicted transmembrane helices (TMHs) between amino acids 1 and 573 are shown as red boxes. One segment is predicted
with less confidence (predicted by 4 of 14 algorithms) and is depicted as a hatched box. The C-terminal catalytic domain is shown in blue and the
GlPDE-specific 35aa-insert between helix 6 and 7 is indicated by a light-blue box. The N-terminal 71 amino acids that were recognized by the program
MitoProtII as mitochondrial-targeting signal are indicated with an orange bar. GlPDE regions 588–1371 and 983–1371 corresponding to the
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fully conserved between the three Giardia genotypes, with the only exception of Ser-1316 that
is replaced by a leucine in isolate P15 of the non-human infective assemblage E (S1 File).
Catalytic domain. The catalytic domain of GlPDE is predicted to conform closely to
those of other class I PDEs of human or parasite origin. It is predicted to form 16 alpha helices
that align well with those of human and kinetoplastid PDEs (Fig 1B). Sequence identity to the
human PDEs varies from 21% (hPDE6A) to 32% (hPDE4D), which is in the range usually
found between different PDE families (S1 Table). All functionally important residues are
highly conserved between GlPDE and the consensus sequence of human PDEs (see S3 Fig).
This includes the purine-scanning invariant glutamine (Gln-1317) and a pair of residues form-
ing a hydrophobic clamp around the nucleobase (P-clamp [53,54] Leu-1279 and Phe-1329), as
well as the eight strictly conserved residues of the metal-binding pocket at the site of catalysis
(His-1068, His-1072, His-1143, Asp-1144, His-1147, Glu-1173, His-1176, Asp-1261).
However, GlPDE also contains some notable differences to the human enzymes. First, a 35
amino acid sequence is inserted into the loop between helix 6 and 7, reminiscent of an insert
also found in hPDE3 isozymes, but the two sequences are not related. Secondly, the GlPDE
catalytic domain contains a unique M-loop connecting helices 14 and 15 (Figs 1B and S5). The
M-loop contributes to the catalytic pocket in human PDEs and is also involved in shaping the
P-pocket of kinetoplastid PDEs and the related “selectivity pocket” of hPDE10, which both are
exploited for inhibitor design [55–57]. The M-loop of GlPDE is the least conserved part of the
catalytic domain as determined by conservation scoring functions (trident/valdar01 [31]).
Interestingly, the H-loop contains a residue, Asp-1151, which is unique in GlPDE in terms
of its physico-chemical properties since all hPDEs contain a polar but uncharged amino acid
(Asn,Thr or Ser) at this position (S3 Fig). In various human and kinetoplastid PDEs the corre-
sponding residue forms a part of the catalytic pocket and has been recognized as an anchor
point for inhibitors to increase isozyme selectivity [58–63].
A further prominent difference between GlPDE and the human PDEs is found outside of
the catalytic cleft (residues Gly-1146 and Ala-1175). These two residues substitute a totally
conserved acidic residue (usually aspartic acid) and an invariant histidine of human PDEs,
respectively (S3 Fig), which have been implicated in forming a structure-stabilizing salt bridge
[64] between the ends of the H-loop. Most importantly, the M-loop and the H-loop are
completely conserved between the sequenced Giardia assemblages A, B and E (S1 File).
GlPDE functionally complements a PDE-deficient S. cerevisiae strain
and hydrolyzes cAMP, but not cGMP in vitro
S. cerevisiae strains lacking both endogenous PDEs display heat-shock sensitivity as a pheno-
type [65]. Functional complementation of this phenotype by heterologous PDE expression has
proven to be a sensitive tool to validate PDE enzyme function [66,43,42]. Since transmem-
brane domains tend to interfere with recombinant expression of proteins, a GlPDE construct
was used that contained the full catalytic domain, but lacked the N-terminal transmembrane
domains (amino acids Met-588 –Glu-1371) (see Fig 1A). The construct was expressed in the
PDE-deficient yeast strain PP5 [66]. As predicted from sequence analysis, the recombinant
recombinant proteins expressed in yeast are marked with grey arrows. (B) Sequence alignment of the catalytic domains (α-helices 3–16) of GlPDE,
human PDE4B, human PDE3B and T. brucei TbrPDEB1. Secondary structure features are shown in dark blue (α-helices) and light blue (310-helices).
α-helices are additionally numbered above the sequences (H3-H16). Residues of the substrate-binding subpocket are indicated with dots above the
alignment. Thereof, the invariant glutamine is additionally marked with an @-sign (highlighted in yellow) and the hydrophobic P-clamp residues are
tagged with green labels. Amino acids that are conserved in all 11 human PDE families and in GlPDE are shown in red letters and indicated with an
asterisk below the alignment. Asterisks are underlined at the eight strictly conserved residues of the metal-binding pocket at the site of catalysis. The
single histidine residue that is conserved among all hPDEs, but is substituted by an alanine in GlPDE (Ala-1175) is marked with a black triangle.
https://doi.org/10.1371/journal.pntd.0005891.g001
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protein was catalytically active, and it fully restored heat-shock resistance of the mutant yeast
strain, also in the presence of an N-terminal HA tag (see Fig 2A). Expression of a truncated
version (see Fig 1A) comprising the catalytic domain solely (Gly-983 to Glu-1371) did not con-
fer heat-shock resistance to the mutant strain.
Fig 2. PDE activity of recombinant GlPDE. (A) The heat-shock phenotype of the PDE-deletion yeast strain
PP5 is complemented by GlPDE. Duplicate patches of recombinant yeast strains were subjected to an initial
heat shock at 55˚C for 15 min (left, +heat shock) or not (right, -heat shock), and were then grown at 30˚C for 2
days.–HA: PP5 expressing GlPDE(aa588-1371); +HA: PP5 expressing GlPDE(aa588-1371) containing an N-
terminal hemagglutinin (HA) tag; CD: PP5 expressing GlPDE(aa983-1371); neg: PP5 transfected with the
empty expression vector (negative control); pos: PP5 expressing the catalytic domain of human PDE4D
(positive control). (B) Michaelis-Menten kinetics of recombinant GlPDE(aa588-1371) with cAMP as substrate.
Insert: Corresponding Hanes plot. All data point determinations were done in triplicate. Square symbols
represent the mean values, and error bars the standard error of the mean (SEM). The shown graph is a
representative example of four experiments.
https://doi.org/10.1371/journal.pntd.0005891.g002
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Soluble lysates prepared from the recombinant yeasts expressing GlPDE(aa588-1371)
hydrolyzed cAMP with standard Michaelis-Menten kinetics with a Km of 408 ± 37 μM (Fig
2B). The enzyme is cAMP-specific and does not accept cGMP as a substrate. No cAMP-hydro-
lyzing activity could be detected in lysates from the parental PP5 strain.
Effect of PDE inhibitors on GlPDE activity and on Giardia trophozoite
proliferation
To pharmacologically validate GlPDE, a selection of 27 PDE inhibitors covering specific
human and trypanosomal PDE families were assessed with cell lysates of recombinant yeast
strain PP5 expressing GlPDE(aa588-1371). This profiling assay showed that most of the
hPDE-family-specific inhibitors were essentially inactive against recombinant GlPDE, even at
100 μM concentration (Fig 3A). In contrast, the two trypanosomal PDE inhibitors NPD-001
and VUF13525, as well as the compounds dipyridamole, PFE-PDE9 (PubChem SID
15099396), roflumilast, piclamilast, and NEU222 showed promising activity against GlPDE.
The same inhibitors were assessed for their activity against the proliferation of G. lamblia tro-
phozoites in culture (Fig 3B). At 50 μM final concentration, most drugs showed no or only
minor anti-giardial activity. However, those compounds that were active against recombinant
GlPDE (roflumilast, piclamilast, PFE-PDE9, NPD-001 and VUF13525) also inhibited Giardia
trophozoite proliferation, with the exception of the non-selective inhibitor dipyridamole.
These data indicate a strong correlation between anti-giardial activity and GlPDE enzyme
inhibition. To confirm our findings, the IC50 values of the compounds found to be active as
shown in Fig 3, and additionally the piclamilast analog NEU222, were determined against
recombinant GlPDE (aa588-1371) and compared to the EC50 values obtained in the cell prolif-
eration assays. Again, there is a good agreement between their potency for enzyme inhibition
and for anti-parasitic activity (Table 1). Representative dose-response curves of the most active
compounds NPD-001 and VUF13525 are given in Fig 4.
The localization pattern of transiently overexpressed GlPDE is
reminiscent of mitosomes and the perinuclear region
In order to investigate the localization of GlPDE in G.lamblia trophozoites, parasites were
transfected with a plasmid encoding a C-terminally HA-tagged copy of GlPDE plus the 200 bp
upstream region containing the putative endogenous promotor, resulting in the transiently
transfected strain PDEp-PDEHA. The subcellular localization of the chimeric protein was
detected by immunofluorescence staining in formaldehyde-fixed cells using an anti-HA anti-
body. The HA-tagged GlPDE was predominantly detected in dot-like patterns in the trophozo-
ite periphery, and at distinct dots that are centrally located between the two nuclei. This
localization pattern may indicate that GlPDE is associated with the various peripheral and the
centrally located mitosomes. Further staining was found in the region surrounding the Giardia
nuclei, which is reminiscent for the endoplasmic reticulum (see Fig 5) [67].
To exclude that GlPDE was localized in endocytic peripheral vesicles (PVs), the transiently
transfected Giardia strain PDEp-PDEHA was first incubated in the presence of Dextran cou-
pled to Alexa Fluor 594 (red), followed by fixation and staining with anti-HA antibodies and a
secondary antibody conjugated to Alexa Fluor 488 (green) (see Fig 6). Microscopy clearly
showed that the red PV staining and the green HA staining signals did not overlap. PVs were
located more distally and were located closely underneath the plasma membrane, whereas the
green anti-HA-labelled structures were found throughout the cell, but were less abundant in
the cellular periphery.
Phosphodiesterase in Giardia lamblia
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Discussion
The present study reports on the identification and characterization of the single PDE from G.
lamblia, GlPDE, and it addresses the question whether this enzyme could represent a valid
drug target. The sequence characteristics unambiguously classify GlPDE as a new member of
the class I PDE superfamily that includes all human and many protozoan parasite PDEs
Fig 3. Effect of human and trypanosomal PDE inhibitors on GlPDE activity and Giardia trophozoite proliferation. (A) Inhibitors were tested at
100 μM against recombinant GlPDE(aa588-1371) enzyme. (B) Trophozoite proliferation after 72h culture in the presence of 50 μM inhibitor.
Compounds that are effective against trophozoites and also impair enzyme activity are indicated with green bars, those inhibiting only either
throphozoite proliferation or GlPDE activity are presented with orange bars. Selectivity of the compounds for different PDE families is shown below the
graphs using grey horizontal bars (non-sel. = non-selective; 1–10 = hPDE1-10; TbrPDEB = T.brucei TbrPDEB1/B2).
https://doi.org/10.1371/journal.pntd.0005891.g003
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[68,27]. GlPDE exhibits many strongly conserved features with the human PDEs, but is also
clearly distinct from them.
The N-terminal half of the protein is predicted to contain eight or nine putative transmem-
brane helices (TMH), of which the first two are predicted to represent a mitochondrial target-
ing signal. The TMH region is followed by a stretch of about 400 amino acids with no
discernible domains, and a C-terminal catalytic domain with a high degree of similarity to
those of the human PDEs.
The presence of such an extended N-terminal transmembrane domain containing two long
extra-membranous regions (~140aa) is a feature that has not been described in other PDEs to
date, though membrane-anchoring through a TMH bundle is also found in many other PDEs
such as in hPDE3 [69] and in all five Plasmodium falciparum PDEs [70].
The prediction of an N-terminal mitochondrial targeting signal in GlPDE is in agreement
with our finding, that HA-tagged GlPDE transiently expressed in Giardia trophozoites
Table 1. Potency of selected PDE inhibitors. From those compounds exhibiting IC50 <100 μM against recombinant GlPDE (aa588-1371) and EC50
<50 μM against Giardia trophozoites in the benchmark screening (see in Fig 3) exact dose responses were determined (values highlighted in green). PDE
activity assays were done in triplicates and repeated at least once (SE of logIC50 < = 0.1), and Giardia cell susceptibility assays were done in quadruplicates
and repeated 2 to 5 times (SE of logEC50 < = 0.15). n.d., not determined.
inhibitor human PDE selectivity Giardia PDE
IC50 (μM)
Giardia cells
EC50 (μM)
IBMX n.s. >100 >50
Pentoxifylline n.s. >100 >50
Dipyridamole 5,6,10,11 26.3 >50
8’-MM-IBMX 1 >100 >50
Vinpocetine 1 >100 16.3
PFE-PDE1 1 >100 >50
EHNA 2 >100 >50
BAY 60–7550 2 >100 ~50
Trequinsin 3 >100 >50
Cilostamide 3 >100 >50
Milrinone 3 >100 >50
Zardaverine 3,4 >100 >50
Rolipram 4 >100 >50
Ro20-1724 4 >100 >50
Roflumilast 4 6.0 7.4
Piclamilast 4 11.3 12.0
NEU222 4 5.1# 5.9
Etazolate 4 ~100 >50
Sildenafil 5 >100 >50
Tadalafil 5 >100 >50
Zaprinast 5 >100 >50
BRL 50481 7 >100 n.d.
BAY 73–6691 9 >100 >50
PFE-PDE9 9 5.8 15.1
Papaverine 10 >100 >50
NEU28 10 ~100 30.6
NPD-001 4, TbrPDEB 0.8 6.9
VUF13525 TbrPDEB 2.3 9.4
#Bottom of the dose-response curve constrained to the background level.
https://doi.org/10.1371/journal.pntd.0005891.t001
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suggests a localization at mitosomes. Mitosomes are organelles that are found in unicellular
microaerophilic or anaerobic organisms such as Entamoeba, microsporidia and Giardia. They
are believed to be derived from mitochondria, but lack the capability to gain energy from oxi-
dative phosphorylation [71,72]. A number of mitosome-associated proteins are closely related
to those of mitochondria [73]. Our tentative association of GlPDE with mitosomes may repre-
sent a further similarity with mitochondria of higher eukaryotes, where cAMP synthesis and
hydrolysis is an important regulatory circuit for mitochondrial metabolism [74,75]. Since
mitosomes do not occur in mammalian cells, but are essential for Giardia and presumably reg-
ulated by cAMP signaling, future studies to verify the localization of GlPDE are certainly
warranted.
With respect to the catalytic domain, all residues important for substrate recognition and
catalysis are conserved between GlPDE and the consensus of human PDEs (S3 Fig). Substrate
specificity of PDEs is determined by a set of approximately twelve residues that define shape
and chemical nature of the subpocket that accommodates the nucleobase [76,77,15]. Concern-
ing these residues, GlPDE conforms best to the cAMP-specific PDEs (S4 Fig). This is in full
agreement with our experimental findings that recombinant GlPDE is cAMP-specific and
does not accept cGMP as a substrate. The observed Km for cAMP of 408 μM is much higher
when compared with hPDEs, where values do not exceed 20 μM for the preferred cyclic nucle-
otide [68]. Although we cannot exclude an artifact of recombinant expression in yeast, class I
PDEs with a high Km for their preferred substrate have been identified in other lower
Fig 4. Representative dose-response curves of the most active compounds. Panels (A) and (C) show
IC50 determinations for NPD-001 and VUF13525 against recombinant GlPDE(aa588-1371) enzyme
(substrate concentration: 1 μM); Panels (B) and (D) show the dose-dependent effect of the same compounds
on proliferation of G. lamblia trophozoites (WB, clone 6), determined after 72 h of anaerobic in vitro culture.
Square symbols represent the mean values of determinations done in triplicate (A,C) or quadruplicate (B,D).
Error bars represent the standard error of the means (SEM).
https://doi.org/10.1371/journal.pntd.0005891.g004
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eukaryotes: For the PDEA orthologs of various kinetoplastid parasites, Km values between 190
and 600 μM have been reported [78,43,79].
The high Km of recombinant GlPDE(aa588-1371) for cAMP indicates that cAMP hydroly-
sis in Giardia occurs with first-order kinetics over a wide concentration range. The presence of
a high-Km PDE as the sole enzyme for cyclic nucleotide degradation is somewhat unusual.
However, a similar case is observed for the fission yeast Schizosaccharomyces pombe. Its
genome codes only for a single class II PDE, Cgs2, that exhibits a high Km for cAMP. Neverthe-
less, this single PDE apparently is sufficient for all aspects of cAMP management, a situation
akin to G. lamblia [80,81].
Other unicellular eukaryotes that express high-Km PDEs usually also express a low-Km
enzyme, though their distinct roles are often not clearly understood. In the yeast S. cerevisiae,
the high-Km, class II PDE, pde1, is the major regulator of agonist-induced cAMP signaling,
while the low-Km, class I PDE, pde2, has only a limited effect on this pathway [82]. In the slime
mold Dictyostelium discoideum, several discrete pools of cAMP exist in the cell, and each is
addressed by a specific pair of PDEs, one of high Km and low capacity, and the second of low
Fig 5. Localization of GlPDE in Giardia trophozoites. C-terminally HA-tagged GlPDE was expressed
under its endogenous promotor in Giardia lamblia trophozoites and detected with a FITC-conjugated anti-HA
antibody. Cells of two independent transient transfections were analyzed by microscopy. An average of
50.6% of the cells were positively stained with the FITC-conjugated antibody and showed signal in discrete
dots in the periphery of the cells and in the perinuclear region. In around 40% of the cells, the chimeric protein
also aligned as—generally three—discrete dots between the two DAPI-stained nuclei, reminiscent of the
central mitosomes. Upper row: Three representative transfected cells (1–3) and wildtype control cell (WB,
clone C6). Lower row: Overlay of the same GlPDE-HA staining (green) with DAPI-stained nuclei (blue).
https://doi.org/10.1371/journal.pntd.0005891.g005
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Km and high capacity. In combination, they are thought to keep the average half-life of cAMP
down, irrespective of fluctuating local concentrations [83]. In the fungal rice pathogen, Mag-
naporthe oryzae, the high-Km PdeH and the low-Km PdeL play unique and non-redundant
roles, with PdeH involved in conidial morphogenesis and PdeL in pathogenic development
[84,85].
In order to pharmacologically evaluate the role of GlPDE, a panel of established PDE inhib-
itors with activity against human and/or trypanosomal PDEs was screened against recombi-
nant GlPDE (aa 588–1371; lacking the N-terminal TMHs). We identified a number of
compounds that inhibited GlPDE in the low micromolar or sub-micromolar concentration
range. All these inhibitors, with the exception of dipyridamole, also impaired Giardia tropho-
zoite proliferation. Interestingly, the compounds with good correlations of biochemical and
cell-biological activities represent four different chemical scaffolds, and thus represent an
excellent starting base for their further development into Giardia-specific PDE inhibitors and
potential drug candidates. In addition, the amino acid sequence differences, and—by infer-
ence—the corresponding structural differences, between human and Giardia PDEs, indicate
Fig 6. Differential localization pattern of GlPDE-HA and internalized dextran in peripheral vesicles.
Peripheral vesicles were loaded with Alexa Fluor 594-coupled dextran (red) and GlPDE-HA was detected with
a FITC-conjugated anti-HA antibody (green). Nuclei were stained with DAPI (blue). The overlay of images
shows completely different patterns of green and red signals. Left column represents a transfected cell, right
column shows a non-transfected control cell.
https://doi.org/10.1371/journal.pntd.0005891.g006
Phosphodiesterase in Giardia lamblia
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005891 September 15, 2017 16 / 23
that a discrimination between human PDEs and GIPDE by appropriate structure optimization
of drug candidates is feasible.
Not surprisingly, a few compounds of the original set exhibited an effect on trophozoite
proliferation, but did not inhibit GlPDE enzyme activity, indicating off-target effects. It could
also mean that such compound targets only the native full-length PDE in the parasite and not
the heterologously expressed GlPDE(aa588-1371) used in the screenings. However, this is
rather unlikely, since almost all known PDE inhibitors target the PDE catalytic pocket [15]. In
the case of BRL50481, the inhibitory effect on trophozoite proliferation may be attributed to
the compound’s nitro-group. Anaerobic organisms such as Giardia reduce nitro-groups to
toxic nitroso derivatives, as it is the case for metronidazole, the current first-line drug against
giardiasis [86]. Off-target effects are also well known for established inhibitors of human
PDEs. Vinpocetine, a classical hPDE1 inhibitor, also co-targets several proteins in addition to
PDE1, such as voltage sensitive Na+ -channels and IKK, a “mediator” of NF-κB action [87–
89]. Thus, this compound is no longer considered a specific PDE inhibitor in whole-cell assay
formats [90].
In conclusion, we show that G. lamblia expresses only a single PDE, which we here charac-
terized on the molecular and functional level. A first pharmacological validation has shown
that targeting GlPDE activity leads to significant impairment of G. lamblia throphozoite prolif-
eration in vitro, which would be an important prerequisite to alleviate giardial disease symp-
toms. These promising findings warrant further studies in vitro and in vivo to exploit GlPDE
as a potential target for the treatment of giardiasis.
Accession numbers
The GiardiaDB (http://www.giardiadb.org) accession numbers for the gene products discussed
in this paper are as follows: (i) GlPDE homologs in different Giardia isolates (assemblage/iso-
late): A/WB (GL50803_14058), A/DH (DHA2_150867), B/GS (GL50581_303), B/GS_B
(GSB_153349), E/P15 (GLP15_4333); (ii) identified putative nucleotidyl cyclases (classIII) in
assemblage A, isolate WB: strong hit (GL50803_14367), strong hit (GL50803_16599), weak hit
(GL50803_16492); (ii) protein kinase A subunits (assemblage A, isolate WB): catalytic subunit
gPKAc (GL50803_11214), regulatory subunit gPKAr (GL50803_9117); (iii) putative phospho-
diesterase SsPDE of S. salmonicida strain ATCC50377 (SS50377_13952).
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